Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity

Ann Neurol. 2008 Jul;64(1):42-52. doi: 10.1002/ana.21287.

Abstract

Objective: Marijuana and alcohol are most widely abused drugs among women of reproductive age. Neurocognitive deficits have been reported in children whose mothers used marijuana during pregnancy. Maternal consumption of ethanol is known to cause serious developmental deficits

Methods: Infant rats and mice received systemic injections of Delta(9)-tetrahydrocannabinol (THC; 1-10mg/kg) or the synthetic cannabinoid WIN 55,212-2 (1-10mg/kg), alone or in combination with subtoxic and toxic ethanol doses, and apoptotic neurodegeneration was studied in the brains

Results: Acute administration of THC (1-10mg/kg), the principal psychoactive cannabinoid of marijuana, markedly enhanced proapoptotic properties of ethanol in the neonatal rat brain. THC did not induce neurodegeneration when administered alone. Neuronal degeneration became disseminated and severe when THC was combined with a mildly intoxicating ethanol dose (3gm/kg), with the effect of this drug combination resembling the massive apoptotic death observed when administering ethanol alone at much higher doses. The detrimental effect of THC was mimicked by the synthetic cannabinoid WIN 55,212-2 (1-10mg/kg) and counteracted by the CB(1) receptor antagonist SR141716A (0.4mg/kg). THC enhanced the proapoptotic effect of the GABA(A) agonist phenobarbital and the N-methyl-D-aspartate receptor antagonist dizocilpine. Interestingly, infant CB(1) receptor knock-out mice were less susceptible to the neurotoxic effect of ethanol. Furthermore, the CB(1) receptor antagonist SR141716A ameliorated neurotoxicity of ethanol

Interpretation: These observations indicate that CB(1) receptor activation modulates GABAergic and glutamatergic neurotransmission and primes the developing brain to suffer apoptotic neuronal death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / physiology*
  • Alcohol-Induced Disorders, Nervous System / chemically induced*
  • Alcohol-Induced Disorders, Nervous System / metabolism
  • Alcohol-Induced Disorders, Nervous System / physiopathology
  • Animals
  • Animals, Newborn
  • Benzoxazines / agonists
  • Benzoxazines / toxicity
  • Brain / drug effects*
  • Brain / growth & development*
  • Brain / physiopathology
  • Cannabinoids / agonists*
  • Cannabinoids / toxicity
  • Cell Death / drug effects
  • Cell Death / physiology
  • Central Nervous System Depressants / agonists
  • Central Nervous System Depressants / toxicity
  • Dose-Response Relationship, Drug
  • Dronabinol / agonists
  • Dronabinol / toxicity
  • Drug Resistance / drug effects
  • Drug Resistance / physiology
  • Drug Synergism
  • Ethanol / agonists*
  • Ethanol / toxicity
  • Excitatory Amino Acid Antagonists / toxicity
  • GABA Agonists / toxicity
  • Mice
  • Mice, Knockout
  • Morpholines / agonists
  • Morpholines / toxicity
  • Naphthalenes / agonists
  • Naphthalenes / toxicity
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / metabolism
  • Nerve Degeneration / physiopathology
  • Neurotoxins / agonists*
  • Neurotoxins / toxicity
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors

Substances

  • Benzoxazines
  • Cannabinoids
  • Central Nervous System Depressants
  • Excitatory Amino Acid Antagonists
  • GABA Agonists
  • Morpholines
  • Naphthalenes
  • Neurotoxins
  • Receptor, Cannabinoid, CB1
  • Ethanol
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Dronabinol